60 acast.com eMultipleSclerosis Review https://podcast.dkbmed.com/category/emultiplesclerosis en DKBmed 2019 eMultipleSclerosis Review eMultipleSclerosis Review podcast channel

Hosted on Acast. See acast.com/privacy for more information.

]]>

Hosted on Acast. See acast.com/privacy for more information.

]]> false eMultipleSclerosis Review info+5fa6db4880850a71c9c4bb45@mg-eu.acast.com 5fa6db4880850a71c9c4bb45 emultiplesclerosisreview https://podcast.dkbmed.com/feed/emultiplesclerosis/ episodic https://assets.pippa.io/shows/5fa6db4880850a71c9c4bb45/1606931215739-ab5a7f1c6cc129ca78cef800652fd7f1.jpeg https://podcast.dkbmed.com/category/emultiplesclerosis eMultipleSclerosis Review https://feeds.acast.com/public/shows/5fa6db4880850a71c9c4bb45 Barriers To Minority Participation in MS Clinical Trials Barriers To Minority Participation in MS Clinical Trials Tue, 25 Mar 2025 10:00:00 GMT 23:57 67a3b4e63eadb4f808fdad44 false https://elit.dkbmed.com/issues/223 67a3b4e63eadb4f808fdad44 5fa6db4880850a71c9c4bb45 barriers-to-minority-participation-in-ms-clinical-trials full 6 12 In the clinical trials of new MS medications and procedures, why has the participation of racial and ethnic minority individuals been so low? Is it a difficulty with outreach? Are the patient barriers to participation underrecognized and underaddressed? Does historical mistrust of the medical community remain a strong negative? What should clinicians and trial designers do to increase diversity to improve care for all individuals with MS?


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/223/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/221)

Hosted on Acast. See acast.com/privacy for more information.

]]> In the clinical trials of new MS medications and procedures, why has the participation of racial and ethnic minority individuals been so low? Is it a difficulty with outreach? Are the patient barriers to participation underrecognized and underaddressed? Does historical mistrust of the medical community remain a strong negative? What should clinicians and trial designers do to increase diversity to improve care for all individuals with MS?


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/223/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/221)

Hosted on Acast. See acast.com/privacy for more information.

]]> <![CDATA[Treating Sexual & Bladder Dysfunction in Patients with MS]]> Tue, 11 Feb 2025 11:00:00 GMT 29:33 678fbbbac4926bdc794c963f false https://elit.dkbmed.com/issues/222 678fbbbac4926bdc794c963f 5fa6db4880850a71c9c4bb45 treating-sexual-bladder-dysfunction-in-patients-with-ms full 6 10 The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/222/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/218)

Hosted on Acast. See acast.com/privacy for more information.

]]> The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/222/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/218)

Hosted on Acast. See acast.com/privacy for more information.

]]> Promising New Options in MS Care Promising New Options in MS Care Fri, 17 Jan 2025 08:00:32 GMT 23:03 6776b525e661dca9eb07096c false https://elit.dkbmed.com/issues/219 6776b525e661dca9eb07096c 5fa6db4880850a71c9c4bb45 promising-new-options-in-ms-care full 6 8 The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/219/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/216)

Hosted on Acast. See acast.com/privacy for more information.

]]> The long-anticipated advances in therapeutic treatments to improve outcomes in both relapsing and progressive MS are coming closer to fruition. Although much of the evidence is still preclinical, the variety and scope of the ongoing research promises to provide new and novel options to manage this disease in the relatively near future.


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/219/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/216)

Hosted on Acast. See acast.com/privacy for more information.

]]> MS and Family Planning: The Clinician’s Perspective MS and Family Planning: The Clinician’s Perspective Fri, 22 Nov 2024 08:00:23 GMT 30:57 673292e847bf92054e0c699d false https://elit.dkbmed.com/issues/215 673292e847bf92054e0c699d 5fa6db4880850a71c9c4bb45 ms-and-family-planning-the-clinicians-perspective full 6 6 Giving birth and raising a family. For many people with MS, the path to achieving those goals contains more questions than answers. Questions about timing — which should come first, pregnancy or disease stability on a DMT? Questions about genetics — can MS be passed on to the baby? Questions about fertility — is in vitro fertilization safe and effective, and how much does it increase disease activity? Questions their treating clinicians may not be able to answer with the most current research.


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/215/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/214)

Hosted on Acast. See acast.com/privacy for more information.

]]> Giving birth and raising a family. For many people with MS, the path to achieving those goals contains more questions than answers. Questions about timing — which should come first, pregnancy or disease stability on a DMT? Questions about genetics — can MS be passed on to the baby? Questions about fertility — is in vitro fertilization safe and effective, and how much does it increase disease activity? Questions their treating clinicians may not be able to answer with the most current research.


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/215/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/214)

Hosted on Acast. See acast.com/privacy for more information.

]]> Clinical Approaches to MS Fatigue Clinical Approaches to MS Fatigue Tue, 15 Oct 2024 14:00:19 GMT 20:15 66fc3448687515ec94f0829e false https://elit.dkbmed.com/issues/211 66fc3448687515ec94f0829e 5fa6db4880850a71c9c4bb45 clinical-approaches-to-ms-fatigue full 6 4 In this issue: Fatigue. It’s one of the most common complaints providers hear from their patients with MS. It interferes with virtually every aspect of a patient’s life. What can clinicians do to better identify MS fatigue? And what do they need to know to better provide management effectively tailored to each patient?


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/211/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/210)

Hosted on Acast. See acast.com/privacy for more information.

]]> In this issue: Fatigue. It’s one of the most common complaints providers hear from their patients with MS. It interferes with virtually every aspect of a patient’s life. What can clinicians do to better identify MS fatigue? And what do they need to know to better provide management effectively tailored to each patient?


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/211/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/210)

Hosted on Acast. See acast.com/privacy for more information.

]]> POMS: A Clinical View POMS: A Clinical View Tue, 17 Sep 2024 13:59:57 GMT 26:02 66d9e3e60ef29103a19303fb false https://elit.dkbmed.com/issues/209 66d9e3e60ef29103a19303fb 5fa6db4880850a71c9c4bb45 poms-a-clinical-view full 6 2 In this issue: POMS. Pediatric Onset Multiple Sclerosis: children and adolescents with symptoms indicating a diagnosis of multiple sclerosis. Are their presentations different from adult-onset MS? POMS is often associated with higher degrees of activity and inflammation early in the disease. How can clinicians most effectively confirm an early MS diagnosis in these young patients? What does the current evidence show about when to prescribe high-efficacy disease modifying therapies? What activity limitations should be placed on patients with POMS?


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/209/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/208)

Hosted on Acast. See acast.com/privacy for more information.

]]> In this issue: POMS. Pediatric Onset Multiple Sclerosis: children and adolescents with symptoms indicating a diagnosis of multiple sclerosis. Are their presentations different from adult-onset MS? POMS is often associated with higher degrees of activity and inflammation early in the disease. How can clinicians most effectively confirm an early MS diagnosis in these young patients? What does the current evidence show about when to prescribe high-efficacy disease modifying therapies? What activity limitations should be placed on patients with POMS?


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/209/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/208)

Hosted on Acast. See acast.com/privacy for more information.

]]> Using the New Biomarkers in Clinical Practice Using the New Biomarkers in Clinical Practice Thu, 05 Sep 2024 16:53:11 GMT 25:55 655e4d0ce121fa00122a8213 false https://shows.acast.com/emultiplesclerosisreview/episodes/using-the-new-biomarkers-in-clinical-practice 655e4d0ce121fa00122a8213 5fa6db4880850a71c9c4bb45 using-the-new-biomarkers-in-clinical-practice full 5 12

Hosted on Acast. See acast.com/privacy for more information.

]]>

Hosted on Acast. See acast.com/privacy for more information.

]]> Emerging MS Clinical Options Emerging MS Clinical Options Wed, 22 Nov 2023 18:54:24 GMT 24:18 65298ed1c0e0c90012f88b7b false https://shows.acast.com/emultiplesclerosisreview/episodes/emerging-ms-clinical-options 65298ed1c0e0c90012f88b7b 5fa6db4880850a71c9c4bb45 emerging-ms-clinical-options full 5 10 Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?


Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/178/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/176)

Hosted on Acast. See acast.com/privacy for more information.

]]> Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?


Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/178/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/176)

Hosted on Acast. See acast.com/privacy for more information.

]]> Clinical and Radiologic Features of an MS Prodrome Clinical and Radiologic Features of an MS Prodrome Wed, 13 Sep 2023 14:43:47 GMT 27:11 64f0affb19942d0012e28259 false https://shows.acast.com/emultiplesclerosisreview/episodes/clinical-and-radiologic-features-of-an-ms-prodrome 64f0affb19942d0012e28259 5fa6db4880850a71c9c4bb45 clinical-and-radiologic-features-of-an-ms-prodrome full 5 8 What’s the evidence supporting the existence of an MS prodromal phase — where the biology of the disease has begun but the symptoms typical of MS have not yet appeared? Are there biomarkers to help identify it? Imaging abnormalities? And how can diagnosing a prodrome benefit patients?

Join us as we discuss these questions with Dr. Naila Makhani from Yale School of Medicine, in this video podcast issue of eMultipleSclerosis Review.


Take our post-test to claim CME credits.

Read this podcast's companion newsletter here.

Hosted on Acast. See acast.com/privacy for more information.

]]> What’s the evidence supporting the existence of an MS prodromal phase — where the biology of the disease has begun but the symptoms typical of MS have not yet appeared? Are there biomarkers to help identify it? Imaging abnormalities? And how can diagnosing a prodrome benefit patients?

Join us as we discuss these questions with Dr. Naila Makhani from Yale School of Medicine, in this video podcast issue of eMultipleSclerosis Review.


Take our post-test to claim CME credits.

Read this podcast's companion newsletter here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Mitigating MS DMT Infection Risk Mitigating MS DMT Infection Risk Thu, 03 Aug 2023 13:53:34 GMT 21:19 6478bf00c0876900116600c2 false https://shows.acast.com/emultiplesclerosisreview/episodes/mitigating-ms-dmt-infection-risk 6478bf00c0876900116600c2 5fa6db4880850a71c9c4bb45 mitigating-ms-dmt-infection-risk full 5 6 Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies — how aware are they of the newer concerns about safety? Which of their patients may be in greater danger of acquiring PML and/or opportunistic infections? The vaccinations commonly recommended for the general population (eg, COVID-19) — do individuals with MS respond differently, and what should clinicians do about it? What do the data say?

Join us, as Dr. Le Hua and Dr. Areeba Siddiqui from the Cleveland Clinic’s Lou Ruvo Center for Brain Health explore these questions in this issue of eMultipleSclerosis Review.


Take our post-test to claim CME credits.

Read this podcast's companion newsletter here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies — how aware are they of the newer concerns about safety? Which of their patients may be in greater danger of acquiring PML and/or opportunistic infections? The vaccinations commonly recommended for the general population (eg, COVID-19) — do individuals with MS respond differently, and what should clinicians do about it? What do the data say?

Join us, as Dr. Le Hua and Dr. Areeba Siddiqui from the Cleveland Clinic’s Lou Ruvo Center for Brain Health explore these questions in this issue of eMultipleSclerosis Review.


Take our post-test to claim CME credits.

Read this podcast's companion newsletter here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Overcoming Barriers to MS Care Overcoming Barriers to MS Care Wed, 19 Jul 2023 16:17:08 GMT 23:08 64ad5ddb48ee2a00113c0aa8 false https://shows.acast.com/emultiplesclerosisreview/episodes/overcoming-barriers-to-ms-care 64ad5ddb48ee2a00113c0aa8 5fa6db4880850a71c9c4bb45 overcoming-barriers-to-ms-care full 5 4 Too many individuals with MS are not receiving access to the most effective care. Why? What’s behind these disparities? And what can individual clinicians do to help remove the barriers that prevent equitable care for all patients?Join us, as Dr. Dorlan Kimbrough, from the division of Neurology, Multiple Sclerosis, and Neuroimmunology at the Duke University School of Medicine, discusses these topics, in this issue of eMultipleSclerosis Review. 


Take our post-test to claim CME credits.

Read this podcast's companion newsletter here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Too many individuals with MS are not receiving access to the most effective care. Why? What’s behind these disparities? And what can individual clinicians do to help remove the barriers that prevent equitable care for all patients?Join us, as Dr. Dorlan Kimbrough, from the division of Neurology, Multiple Sclerosis, and Neuroimmunology at the Duke University School of Medicine, discusses these topics, in this issue of eMultipleSclerosis Review. 


Take our post-test to claim CME credits.

Read this podcast's companion newsletter here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Clinical Opinions: Managing Spasticity in Individuals with MS Clinical Opinions: Managing Spasticity in Individuals with MS Fri, 12 May 2023 04:01:53 GMT 41:50 645548d4cfaa0e0012d6d6e5 false https://shows.acast.com/emultiplesclerosisreview/episodes/clinical-opinions-managing-spasticity-in-individuals-with-ms 645548d4cfaa0e0012d6d6e5 5fa6db4880850a71c9c4bb45 clinical-opinions-managing-spasticity-in-individuals-with-ms full How burdensome is spasticity for patients with MS? What’s the approach to treatment, and how effective is it? What do patients and clinicians need to know about cannabis-based therapies?  

These are the key questions Program Director Dr. Michael Kornberg from the Johns Hopkins School of Medicine discusses with guest MS spasticity experts in this second part of this eMultipleSclerosis Review Special Edition. 


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> How burdensome is spasticity for patients with MS? What’s the approach to treatment, and how effective is it? What do patients and clinicians need to know about cannabis-based therapies?  

These are the key questions Program Director Dr. Michael Kornberg from the Johns Hopkins School of Medicine discusses with guest MS spasticity experts in this second part of this eMultipleSclerosis Review Special Edition. 


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> MS Risk Factors and Outcomes MS Risk Factors and Outcomes Wed, 08 Mar 2023 15:44:03 GMT 17:34 63fcc6f4d326430011e677f3 false https://shows.acast.com/emultiplesclerosisreview/episodes/ms-risk-factors-and-outcomes 63fcc6f4d326430011e677f3 5fa6db4880850a71c9c4bb45 ms-risk-factors-and-outcomes full 5 2 In her Expert Commentary, Dr. Melanie Ward from West Virginia University’s Rockefeller Neuroscience Institute provided analysis of the newer data describing the modifiable and nonmodifiable risk factors for developing MS and/or increasing the rate of disease progression and disability.

Join us for this podcast as Dr. Ward explains how these findings can affect clinical practice to improve overall care of individuals with MS. 


Take our post-test to claim CME credits.

Read this podcast's companion newsletter here.

Hosted on Acast. See acast.com/privacy for more information.

]]> In her Expert Commentary, Dr. Melanie Ward from West Virginia University’s Rockefeller Neuroscience Institute provided analysis of the newer data describing the modifiable and nonmodifiable risk factors for developing MS and/or increasing the rate of disease progression and disability.

Join us for this podcast as Dr. Ward explains how these findings can affect clinical practice to improve overall care of individuals with MS. 


Take our post-test to claim CME credits.

Read this podcast's companion newsletter here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Effects of Race/Ethnicity on MS Diagnosis and Treatment Effects of Race/Ethnicity on MS Diagnosis and Treatment Wed, 05 Oct 2022 15:37:46 GMT 20:52 6322450c1c230f0011e6b944 false https://shows.acast.com/emultiplesclerosisreview/episodes/effects-of-raceethnicity-on-ms-diganosis-and-treatment 6322450c1c230f0011e6b944 5fa6db4880850a71c9c4bb45 effects-of-raceethnicity-on-ms-diganosis-and-treatment full 4 12 How aware are clinicians that MS should no longer be considered a “White people only” disease? What roles have race and ethnicity been shown to play in MS disease severity and disability progression? What do health care professionals need to know to provide the most effective care for all their patients?

Join Dr. Yujie Wang from the University of Washington and Dr. Kimystian Harrison, a post doctoral fellow at Johns Hopkins University, as they explore these and other questions in this eMultipleSclerosis Review podcast.


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> How aware are clinicians that MS should no longer be considered a “White people only” disease? What roles have race and ethnicity been shown to play in MS disease severity and disability progression? What do health care professionals need to know to provide the most effective care for all their patients?

Join Dr. Yujie Wang from the University of Washington and Dr. Kimystian Harrison, a post doctoral fellow at Johns Hopkins University, as they explore these and other questions in this eMultipleSclerosis Review podcast.


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Clinical Considerations for In-Development MS Treatments Clinical Considerations for In-Development MS Treatments Thu, 25 Aug 2022 05:16:18 GMT 24:41 62fcf32c455475001243b41a false https://shows.acast.com/emultiplesclerosisreview/episodes/clinical-considerations-for-in-development-ms-treatments 62fcf32c455475001243b41a 5fa6db4880850a71c9c4bb45 clinical-considerations-for-in-development-ms-treatments full 4 10 Where’s the newer MS research leading? How has our understanding of noninflammatory progressive MS changed? How might these findings affect what happens in the clinic? 

Join us as we discuss these and other questions with Dr. Michael Kornberg from the Johns Hopkins School of Medicine in this eMultipleSclerosis Review podcast. 


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Where’s the newer MS research leading? How has our understanding of noninflammatory progressive MS changed? How might these findings affect what happens in the clinic? 

Join us as we discuss these and other questions with Dr. Michael Kornberg from the Johns Hopkins School of Medicine in this eMultipleSclerosis Review podcast. 


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Is that MS Diagnosis Accurate? Is that MS Diagnosis Accurate? Wed, 08 Jun 2022 13:34:05 GMT 25:39 62588404295dac001342018c false https://shows.acast.com/emultiplesclerosisreview/episodes/is-that-ms-diagnosis-accurate 62588404295dac001342018c 5fa6db4880850a71c9c4bb45 is-that-ms-diagnosis-accurate full 4 8 Is it true that a significant number of patients being treated for MS may not actually have the disease? What are the red flags — warnings that something about the patient’s condition does not meet the accepted MS diagnostic criteria — that need to be investigated?   

Join us in this eMultipleSclerosis Review podcast, as Neuroimmunologist Dr. Gabrielle Macaron from Saint Joseph University’s Hotel Dieu de France Hospital in Beirut, Lebanon, and the Cleveland Clinic’s Mellen Center for Multiple Sclerosis, explains strategies to reduce misdiagnosis of MS. 


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Is it true that a significant number of patients being treated for MS may not actually have the disease? What are the red flags — warnings that something about the patient’s condition does not meet the accepted MS diagnostic criteria — that need to be investigated?   

Join us in this eMultipleSclerosis Review podcast, as Neuroimmunologist Dr. Gabrielle Macaron from Saint Joseph University’s Hotel Dieu de France Hospital in Beirut, Lebanon, and the Cleveland Clinic’s Mellen Center for Multiple Sclerosis, explains strategies to reduce misdiagnosis of MS. 


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Nonpharmacologic Symptom Management Nonpharmacologic Symptom Management Tue, 10 May 2022 12:33:16 GMT 25:56 626c4d76f8d6df0012768f88 false https://shows.acast.com/emultiplesclerosisreview/episodes/nonpharmacologic-symptom-management 626c4d76f8d6df0012768f88 5fa6db4880850a71c9c4bb45 nonpharmacologic-symptom-management full 4 6 In this Issue: Fatigue. Urinary dysfunction. Constipation. Spasticity and gait problems. Providing relief from these common MS symptoms often requires clinicians to go beyond the prescription pad to recommend nonpharmacologic treatments. What works? What doesn’t? What does the evidence say? 


Join us as Dr. W. Oliver Tobin from the Mayo Clinic discusses these questions in this eMultipleSclerosis Review podcast.


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> In this Issue: Fatigue. Urinary dysfunction. Constipation. Spasticity and gait problems. Providing relief from these common MS symptoms often requires clinicians to go beyond the prescription pad to recommend nonpharmacologic treatments. What works? What doesn’t? What does the evidence say? 


Join us as Dr. W. Oliver Tobin from the Mayo Clinic discusses these questions in this eMultipleSclerosis Review podcast.


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Treatment Considerations for Aging Patients Treatment Considerations for Aging Patients Tue, 08 Mar 2022 15:13:52 GMT 23:28 6227716e6f48ef0012340045 false https://shows.acast.com/emultiplesclerosisreview/episodes/treatment-considerations-for-aging-patients 6227716e6f48ef0012340045 5fa6db4880850a71c9c4bb45 treatment-considerations-for-aging-patients full 4 4 As people with MS age, how does their response to their long-term DMT change? Is there a time when disease-modifying therapy can be safely discontinued? In which patients? At what age? What role do comorbidities play in making these decisions?  

Join us as we discuss these questions with Dr. Burcu Zeydan from the Mayo Clinic in this eMultipleSclerosis Review podcast. 


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> As people with MS age, how does their response to their long-term DMT change? Is there a time when disease-modifying therapy can be safely discontinued? In which patients? At what age? What role do comorbidities play in making these decisions?  

Join us as we discuss these questions with Dr. Burcu Zeydan from the Mayo Clinic in this eMultipleSclerosis Review podcast. 


Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> MS and the COVID-19 Vaccine: What Do We Know and What Should We Do About It?  MS and the COVID-19 Vaccine: What Do We Know and What Should We Do About It?  Wed, 08 Dec 2021 18:52:38 GMT 16:44 61b0fef692e48b001381f716 false https://elit.dkbmed.com/issues/119 61b0fef692e48b001381f716 5fa6db4880850a71c9c4bb45 emsv4e1 full 4 2 COVID-19 vaccination. For many people with multiple sclerosis, it’s not a simple and straightforward process. The DMT they’re currently taking to control disease progression and moderate their symptoms — particularly if it’s a beta cell- depleting agent — may prevent the vaccine from working as it’s supposed to. What do clinicians need to know, and how should they explain it to their patients?  


Dr. Joseph Sabatino from the University of California San Francisco presented the basics in his recent newsletter issue; now he brings that information into the clinic in this eMultipleSclerosis Review podcast. 


Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> COVID-19 vaccination. For many people with multiple sclerosis, it’s not a simple and straightforward process. The DMT they’re currently taking to control disease progression and moderate their symptoms — particularly if it’s a beta cell- depleting agent — may prevent the vaccine from working as it’s supposed to. What do clinicians need to know, and how should they explain it to their patients?  


Dr. Joseph Sabatino from the University of California San Francisco presented the basics in his recent newsletter issue; now he brings that information into the clinic in this eMultipleSclerosis Review podcast. 


Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Shared Decision Making in MS: The Why and The How Shared Decision Making in MS: The Why and The How Fri, 23 Apr 2021 18:32:50 GMT 21:20 6083128e6aa7ef4bc7168e93 false https://elit.dkbmed.com/issues/109 6083128e6aa7ef4bc7168e93 5fa6db4880850a71c9c4bb45 shared-decision-making-in-ms-the-why-and-the-how full 3 12 Shared decision-making — what does it mean in multiple sclerosis? Can it really help providers more fully understand their patients’ concerns? Can it motivate patients to more readily and enthusiastically take ownership of their disease? And most important, how can it be developed in the clinic? 


Join us in this eMultipleSclerosis Review podcast, as we talk about the why and how of shared decision-making in MS with PA Lisa Fox from the Department of Neurology at Johns Hopkins Hospital in Baltimore.  


Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Shared decision-making — what does it mean in multiple sclerosis? Can it really help providers more fully understand their patients’ concerns? Can it motivate patients to more readily and enthusiastically take ownership of their disease? And most important, how can it be developed in the clinic? 


Join us in this eMultipleSclerosis Review podcast, as we talk about the why and how of shared decision-making in MS with PA Lisa Fox from the Department of Neurology at Johns Hopkins Hospital in Baltimore.  


Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Clinical Approaches and DMT Choices Clinical Approaches and DMT Choices Wed, 10 Mar 2021 13:55:59 GMT 23:08 6022bdb1b6138e6bf8530451 false https://elit.dkbmed.com/issues/102 6022bdb1b6138e6bf8530451 5fa6db4880850a71c9c4bb45 clinical-approaches-and-dmt-choices full 3 10 As the number of new MS therapies continues to grow, so does the uncertainty about which management approach — escalation or highly effective disease-modifying therapy — is best for each patient. What are the patient-specific factors that indicate the most appropriate DMT selection? What’s known about the potential longer-term risks associated with highly effective therapies? 


That’s the focus of our discussion with Dr. Yujie Wang from the University of Washington and Johns Hopkins University, and Dr. Anne Damian-Yacoub from Johns Hopkins University in this eMultipleSclerosis Review podcast. 


Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> As the number of new MS therapies continues to grow, so does the uncertainty about which management approach — escalation or highly effective disease-modifying therapy — is best for each patient. What are the patient-specific factors that indicate the most appropriate DMT selection? What’s known about the potential longer-term risks associated with highly effective therapies? 


That’s the focus of our discussion with Dr. Yujie Wang from the University of Washington and Johns Hopkins University, and Dr. Anne Damian-Yacoub from Johns Hopkins University in this eMultipleSclerosis Review podcast. 


Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> A Clinical Approach to Comprehensive MS Care A Clinical Approach to Comprehensive MS Care Tue, 02 Feb 2021 22:14:56 GMT 31:35 600f2de994295616f6e9272a false https://elit.dkbmed.com/issues/100 600f2de994295616f6e9272a 5fa6db4880850a71c9c4bb45 a-clinical-approach-to-comprehensive-ms-care full A “comprehensive MS center” — what is it? Which clinicians comprise a “multidisciplinary MS care team?” How does comprehensive MS care work in practice? How does it benefit patients?


That’s the focus of this non-CME-accredited eMultipleSclerosis Review podcast, where we answer those questions and more, with our special guest, Dr. Jacqueline Nicholas, System Chief of Neuroimmunology and Multiple Sclerosis at the OhioHealth Multiple Sclerosis Center.  


Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> A “comprehensive MS center” — what is it? Which clinicians comprise a “multidisciplinary MS care team?” How does comprehensive MS care work in practice? How does it benefit patients?


That’s the focus of this non-CME-accredited eMultipleSclerosis Review podcast, where we answer those questions and more, with our special guest, Dr. Jacqueline Nicholas, System Chief of Neuroimmunology and Multiple Sclerosis at the OhioHealth Multiple Sclerosis Center.  


Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Clinical Challenges of Pediatric MS Clinical Challenges of Pediatric MS Sun, 27 Dec 2020 11:00:07 GMT 20:35 5fd7ca01451f326f685f8d9e false https://elit.dkbmed.com/issues/95 5fd7ca01451f326f685f8d9e 5fa6db4880850a71c9c4bb45 clinical-challenges-of-pediatric-ms The  differences in MS disease activity between children and adults. full 3 8 Pediatric multiple sclerosis. How different is the disease from adult MS? Which disease-modifying therapies have been trialed and approved for use in children? How common is cognitive impairment in children with MS? How can it be successfully addressed?  


These are some of the important questions Drs. Zongqi Xia and Kavita Thakkar from the University of Pittsburgh Medical Center discuss in this clinically focused eMultipleSclerosis Review podcast. 


Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Pediatric multiple sclerosis. How different is the disease from adult MS? Which disease-modifying therapies have been trialed and approved for use in children? How common is cognitive impairment in children with MS? How can it be successfully addressed?  


These are some of the important questions Drs. Zongqi Xia and Kavita Thakkar from the University of Pittsburgh Medical Center discuss in this clinically focused eMultipleSclerosis Review podcast. 


Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Clinical Decisions: Selecting the Right Disease Modifying Therapy Clinical Decisions: Selecting the Right Disease Modifying Therapy Wed, 21 Oct 2020 09:00:00 GMT 21:31 https://podcast.dkbmed.com/?p=990 false https://shows.acast.com/emultiplesclerosisreview/episodes/5fa6db53e079dc4e5c6bd9ac 5fa6db53e079dc4e5c6bd9ac 5fa6db4880850a71c9c4bb45 The safety and efficacy of newly approved oral MS therapies. The differences between the induction and escalation approaches to MS treatment. full 3 6 Selecting the most appropriate Disease Modifying Therapy (DMT) is becoming more complicated for patients with MS and clinicians who treat them. Newer approaches and newer agents are altering the benefit/risk equation, and making the question of which treatment is most appropriate for which patient more difficult to answer. 

That’s the focus of our discussion with Dr. Erin Longbrake, Assistant Professor of Neurology and Director of the Multiple Sclerosis Fellowship Program at Yale University, in this eMultipleSclerosis Review podcast. 

Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Selecting the most appropriate Disease Modifying Therapy (DMT) is becoming more complicated for patients with MS and clinicians who treat them. Newer approaches and newer agents are altering the benefit/risk equation, and making the question of which treatment is most appropriate for which patient more difficult to answer. 

That’s the focus of our discussion with Dr. Erin Longbrake, Assistant Professor of Neurology and Director of the Multiple Sclerosis Fellowship Program at Yale University, in this eMultipleSclerosis Review podcast. 

Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Clinic Insight — Managing Chronic MS Symptoms Clinic Insight — Managing Chronic MS Symptoms Thu, 13 Aug 2020 21:45:09 GMT 17:48 https://podcast.dkbmed.com/?p=904 false https://shows.acast.com/emultiplesclerosisreview/episodes/5fa6db53e079dc4e5c6bd9ad 5fa6db53e079dc4e5c6bd9ad 5fa6db4880850a71c9c4bb45 Chronic MS symptoms and their effects on quality of life. full 3 4 Successful management of multiple sclerosis has gone beyond slowing disease progression and preventing relapses. Improving patients’ health-related quality of life by recognizing and addressing the pervasive chronic symptoms of the disease — spasticity, fatigue, depression, cognitive dysfunction — has become increasingly important.


In this eMultipleSclerosis Review Podcast, Dr. Bardia Nourbakhsh from the Johns Hopkins School of Medicine provides clinical insight into reducing the disease burden of these common symptoms. 

Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Successful management of multiple sclerosis has gone beyond slowing disease progression and preventing relapses. Improving patients’ health-related quality of life by recognizing and addressing the pervasive chronic symptoms of the disease — spasticity, fatigue, depression, cognitive dysfunction — has become increasingly important.


In this eMultipleSclerosis Review Podcast, Dr. Bardia Nourbakhsh from the Johns Hopkins School of Medicine provides clinical insight into reducing the disease burden of these common symptoms. 

Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Minimizing Pregnancy/Postpartum Relapses: A Clinical Perspective Minimizing Pregnancy/Postpartum Relapses: A Clinical Perspective Wed, 01 Jul 2020 06:00:00 GMT 21:03 https://podcast.dkbmed.com/?p=849 false https://shows.acast.com/emultiplesclerosisreview/episodes/5fa6db53e079dc4e5c6bd9ae 5fa6db53e079dc4e5c6bd9ae 5fa6db4880850a71c9c4bb45 The risk factors for postpartum MS relapses. Pregnancy planning and management strategies to moderate the risk of MS relapses. full 3 2 Disease reactivation during and after pregnancy is a challenge facing many women with MS and their clinicians. How can relapses be prevented? What are the benefits of pregnancy planning? What are the risk factors for postpartum MS reactivation? How can they be modified? 

These are the questions Dr. Kristen Krysko from the University of California San Francisco addresses in this eMultipleSclerosis Review podcast.  

Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Disease reactivation during and after pregnancy is a challenge facing many women with MS and their clinicians. How can relapses be prevented? What are the benefits of pregnancy planning? What are the risk factors for postpartum MS reactivation? How can they be modified? 

These are the questions Dr. Kristen Krysko from the University of California San Francisco addresses in this eMultipleSclerosis Review podcast.  

Take our post-test to claim CME credits.


To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Individualizing MS Treatment: Practical Applications Individualizing MS Treatment: Practical Applications Sat, 29 Jun 2019 06:00:49 GMT 25:11 https://podcast.dkbmed.com/?p=666 false https://shows.acast.com/emultiplesclerosisreview/episodes/5fa6db53e079dc4e5c6bd9af 5fa6db53e079dc4e5c6bd9af 5fa6db4880850a71c9c4bb45 The challenges in developing new MS therapies. The practical applications of individualizing MS therapy. full 2 6 In this podcast, Drs. Daniel Ontaneda, Jenny Feng and Gabrielle Macaron from the Cleveland Clinic follow up on their recent eMS Newsletter Issue (V2; No.5) to discuss some of the practical applications of individualizing MS therapy.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> In this podcast, Drs. Daniel Ontaneda, Jenny Feng and Gabrielle Macaron from the Cleveland Clinic follow up on their recent eMS Newsletter Issue (V2; No.5) to discuss some of the practical applications of individualizing MS therapy.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Patients’ DMT Decision-Making Patients’ DMT Decision-Making Fri, 19 Apr 2019 06:00:14 GMT 24:08 https://podcast.dkbmed.com/?p=657 false https://shows.acast.com/emultiplesclerosisreview/episodes/5fa6db53e079dc4e5c6bd9b0 5fa6db53e079dc4e5c6bd9b0 5fa6db4880850a71c9c4bb45 The communications issues that influence patients’ disease-modifying therapy decision-making. Potential strategies for addressing comorbidities in the clinical care of individuals with MS. full 2 4 In this issue, Dr. Ellen Mowry, Associate Professor of Neurology and Epidemiology at the Johns Hopkins University School of Medicine, brings recent findings about patient decision-making and addressing common comorbidities into the MS clinic.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> In this issue, Dr. Ellen Mowry, Associate Professor of Neurology and Epidemiology at the Johns Hopkins University School of Medicine, brings recent findings about patient decision-making and addressing common comorbidities into the MS clinic.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Clinical Markers for MS Diagnosis and Prognosis Clinical Markers for MS Diagnosis and Prognosis Mon, 25 Feb 2019 15:52:45 GMT 27:08 https://podcast.dkbmed.com/?p=635 false https://shows.acast.com/emultiplesclerosisreview/episodes/5fa6db53e079dc4e5c6bd9b1 5fa6db53e079dc4e5c6bd9b1 5fa6db4880850a71c9c4bb45 The role of emerging biomarkers, including optical coherence tomography and serum neurofilament light chain, in predicting future disability in MS. full 2 2 The central vein sign. Optical coherence tomography. Serum neurofilament light chain. New research has identified these markers as valuable in discriminating MS from mimicking conditions, and in predicting future disability.

In this Issue, Dr. Michael Kornberg and Dr. Elias Sotirchos from the Johns Hopkins University School of Medicine discuss how these advances can impact clinical decision-making to provide better patient care.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> The central vein sign. Optical coherence tomography. Serum neurofilament light chain. New research has identified these markers as valuable in discriminating MS from mimicking conditions, and in predicting future disability.

In this Issue, Dr. Michael Kornberg and Dr. Elias Sotirchos from the Johns Hopkins University School of Medicine discuss how these advances can impact clinical decision-making to provide better patient care.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Incorporating MRI Results in Treatment Decision Making Incorporating MRI Results in Treatment Decision Making Thu, 19 Nov 2015 06:00:24 GMT 31:56 https://podcast.dkbmed.com/?p=438 false https://shows.acast.com/emultiplesclerosisreview/episodes/5fa6db53e079dc4e5c6bd9b2 5fa6db53e079dc4e5c6bd9b2 5fa6db4880850a71c9c4bb45 Incorporating MRI Results in Treatment Decision Making. full 1 6 Benjamin M. Greenberg, MD, MHS covers the important topic of Incorporating MRI Results in Treatment Decision Making in the format of case-study scenarios for the clinical practice.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Benjamin M. Greenberg, MD, MHS covers the important topic of Incorporating MRI Results in Treatment Decision Making in the format of case-study scenarios for the clinical practice.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> New Insights into Lifestyle Modification New Insights into Lifestyle Modification Tue, 13 Oct 2015 06:00:04 GMT 33:19 https://podcast.dkbmed.com/?p=440 false https://shows.acast.com/emultiplesclerosisreview/episodes/5fa6db53e079dc4e5c6bd9b3 5fa6db53e079dc4e5c6bd9b3 5fa6db4880850a71c9c4bb45 New Insights into Lifestyle Modification. full 1 4 Ellen M. Mowry, MD, MCR covers the important topic of New Insights into Lifestyle Modification in the format of case-study scenarios for the clinical practice.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Ellen M. Mowry, MD, MCR covers the important topic of New Insights into Lifestyle Modification in the format of case-study scenarios for the clinical practice.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Personalizing DMT Regimens/The Risks of Medication Non-Adherence Personalizing DMT Regimens/The Risks of Medication Non-Adherence Fri, 18 Sep 2015 06:00:34 GMT 32:11 https://podcast.dkbmed.com/?p=442 false https://shows.acast.com/emultiplesclerosisreview/episodes/5fa6db53e079dc4e5c6bd9b4 5fa6db53e079dc4e5c6bd9b4 5fa6db4880850a71c9c4bb45 Personalizing DMT regimens and the risk of medication non-adherence. full 1 2 Arun Venkatesan, MD, PhD and Scott Douglas Newsome, DO cover the important topics of personalizing DMT regimens and the risk of medication non-adherence in the format of case-study scenarios for the clinical practice.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]> Arun Venkatesan, MD, PhD and Scott Douglas Newsome, DO cover the important topics of personalizing DMT regimens and the risk of medication non-adherence in the format of case-study scenarios for the clinical practice.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.

]]>